A review of its effects in schizophrenia suggests that modafinil facilitates cognitive functions , with pro-mnemonic effects and problem solving improvements .
The systematic review on the neurochemical modulation of the modafinil suggests that its mnemonic enhancing properties might be the result of glutamatergic and dopaminergic increased neuronal activation in the hippocampus and in the prefrontal cortex respectively .
Other neurotransmitters were also activated by modafinil in various limbic brain areas , suggesting that the drug acts on these brain regions to influence emotional responses .
Modafinil is a central nervous system wake promoting agent used for the treatment of excessive daytime sleeping .
Its vigilance promoting properties and low abuse potential has intrigued the scientific community and has led to use it as a cognitive enhancer , before its neural functions were understood .
Here , we review the effects of modafinil in human cognition and emotion and its specific actions on symptoms in patients with schizophrenia and whether these are consistently effective throughout the literature .
We also performed a systematic review on the effects of modafinil on neurotransmitter signalling in different areas of the brain in order to better underst and the neuromechanisms of its cognitive and emotional enhancing properties .
Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life.
OBJECTIVE We evaluated the effects of modafinil , a wake-promoting agent , on patient functioning , health-related quality of life , and nighttime and daytime sleep in patients with excessive sleepiness associated with shift work sleep disorder ( SWSD ) . METHOD A 12-week , r and omized , double-blind , placebo-controlled study was performed at 31 centers in the United States between February 2001 and March 2002 . Adults ( N = 278 ) with excessive sleepiness associated with chronic SWSD ( International Classification of Sleep Disorders criteria ) were r and omly assigned to receive modafinil 200 or 300 mg or placebo , 30 to 60 minutes before each night shift . Effects on patient functioning and quality of life were assessed using the Functional Outcomes of Sleep Question naire ( FOSQ ) and the 36-item Short Form Health Survey ( SF-36 ) , respectively . Daily patient diaries were used as a sleep log . RESULTS Modafinil 300 mg significantly improved mean FOSQ total score relative to placebo ( 2.3-point increase from baseline vs. 1.6 for placebo ; p < .05 ) . Both doses of modafinil significantly improved mean SF-36 mental component scores relative to placebo ( mean changes from baseline of 3.2 , 3.7 , and 0.7 points in the modafinil 300-mg , modafinil 200-mg , and placebo groups , respectively ; p < .05 for each comparison vs. placebo ) . Modafinil did not adversely affect sleep when sleep was desired or caffeine use . Modafinil was well tolerated . Headache ( 21.5 % ) and nausea ( 12.4 % ) were the most common adverse events in modafinil-treated patients . Differences between modafinil and placebo for vital sign measurements , physical examination findings , or electrocardiography results were not clinical ly meaningful . CONCLUSIONS Modafinil significantly improves functioning and quality of life in patients with SWSD . Modafinil is an effective treatment for excessive sleepiness associated with SWSD
A review of its effects in schizophrenia suggests that modafinil facilitates cognitive functions , with pro-mnemonic effects and problem solving improvements .
The systematic review on the neurochemical modulation of the modafinil suggests that its mnemonic enhancing properties might be the result of glutamatergic and dopaminergic increased neuronal activation in the hippocampus and in the prefrontal cortex respectively .
Other neurotransmitters were also activated by modafinil in various limbic brain areas , suggesting that the drug acts on these brain regions to influence emotional responses .
Modafinil is a central nervous system wake promoting agent used for the treatment of excessive daytime sleeping .
Its vigilance promoting properties and low abuse potential has intrigued the scientific community and has led to use it as a cognitive enhancer , before its neural functions were understood .
Here , we review the effects of modafinil in human cognition and emotion and its specific actions on symptoms in patients with schizophrenia and whether these are consistently effective throughout the literature .
We also performed a systematic review on the effects of modafinil on neurotransmitter signalling in different areas of the brain in order to better underst and the neuromechanisms of its cognitive and emotional enhancing properties .